The trial was conducted by Sagimet’s license partner for China, Ascletis Bioscience Co., in 480 patients with moderate to ...

Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis ...

Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical ...

A persistent myth is that acne results from poor hygiene. It’s an understandable assumption given that bacteria play a role, but it’s wrong. Acne doesn’t develop because the skin is dirty, and ...

SAN DIEGO, Feb. 11, 2020 /PRNewswire/ -- Dermata Therapeutics, LLC, a privately held biotechnology company, announced today that it has completed enrollment of patients in its Phase 2b clinical trial ...

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — A rapid improvement in severe acne was observed in patients treated with 12 weeks of trifarotene and ...

Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026 Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion More ...

Denifanstat met all endpoints in a Phase 3 acne trial and showed favorable tolerability. Sagimet also launched a Phase 1 trial for TVB-3567. Sagimet Biosciences announced that its oral fatty acid ...